Predictors of adherence and virologic outcome in HIV-infected patients treated with abacavir- or indinavir-based triple combination HAART also containing lamivudine/zidovudine

Current Medical Research and Opinion

Volumn 20, Issue 7, 2004, Pages 1115-1123

  Cahn, Pedro ^a   Vibhagool, Asda ^b   Schechter, Mauro ^c   Soto Ramirez, Luis ^d   Carosi, Giampiero ^e   Smaill, Fiona ^f   Jordan, Jamie C ^g   Pharo, Cristina E ^h   Thomas, Nicola E ^h   Steel, Helen M ^h  

^a FUNDACIÓN HUÉSPED   (Argentina)

^b MAHIDOL UNIVERSITY   (Thailand)

^c FEDERAL UNIVERSITY OF RIO DE JANEIRO   (Brazil)

^d INSTITUTO NACIONAL DE CIENCIAS MÉDICAS Y NUTRICIÓN SALVADOR ZUBIRÁN   (Mexico)

^e UNIVERSITY OF BRESCIA   (Italy)

^f MCMASTER UNIVERSITY MEDICAL CENTRE   (Canada)

^g GLAXOSMITHKLINE   (United States)

^h GLAXOSMITHKLINE   (United Kingdom)

Author keywords

Abacavir; Adherence; Combination antiretroviral therapy; Combination tablet; Indinavir; Lamivudine zidovudine

Indexed keywords

ABACAVIR; INDINAVIR; LAMIVUDINE PLUS ZIDOVUDINE;

ADULT; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; FEMALE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LOGISTIC REGRESSION ANALYSIS; LYMPHOCYTE COUNT; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; OPEN STUDY; PATIENT COMPLIANCE; PREDICTION; RANDOMIZED CONTROLLED TRIAL; TREATMENT OUTCOME; VIRUS LOAD;

ADULT; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; DIDEOXYNUCLEOSIDES; DRUG COMBINATIONS; DRUG THERAPY, COMBINATION; FEMALE; HIV INFECTIONS; HIV PROTEASE INHIBITORS; HIV-1; HUMANS; INDINAVIR; LAMIVUDINE; MALE; PATIENT COMPLIANCE; REVERSE TRANSCRIPTASE INHIBITORS; RISK FACTORS; TREATMENT OUTCOME; ZIDOVUDINE;

EID: 3242735090     PISSN: 03007995     EISSN: None     Source Type: Journal    
DOI: 10.1185/030079904125004051     Document Type: Article

References (16)

1. Casado J, Sabido R, Perez-Elias M, et al. Percentage of adherence correlates with the risk of protease inhibitor (PI) treatment failure in HIV-infected patients. Antivir Ther 1999;4:157-61
2. Paterson D, Swindells S, Mohr J, et al. Adherence to protease inhibitor therapy and outcomes in patients with HIV infection. Ann Intern Med;1997;133:21-30
3. Low-Beer S, Yip B, O'Shaughnessy MV, Hogg RS, Montaner JSG. Adherence to triple therapy and viral load response [letter]. J Acquir Immune Defic Syndr 2000;23:360-1
4. Bangsberg, D, Perry S, Charlebois R, et al. Non-adherence to highly active antiretroviral therapy predicts progression to AIDS. AIDS 2001;15:1181-3
5. 9 cells/L. Ann Intern Med 2003;139:810-816
6. Roberts KJ. Barriers to and facilitators of HIV-positive patients' adherence to antiretroviral treatment regimens. AIDS Patient Care and STDs 2000;14:155-68
7. Proctor V, Tesfa A, Tompkins D. Barriers to adherence to highly active antiretroviral therapy as expressed by people living with HIV/AIDS. AIDS Patient Care and STDs 1999;13:535-44
8. Jordan J, Carranza Rosenzweig J, Pathak D, Pilon T. Perceived impact of regimen characteristics on adherence. Fifth international congress on drug therapy in HIV infection. Glasgow, UK, 22-26 October 2000 [Abstract 396]
9. Bartlett JA, DeMasi R, Quinn J, Moxham C, Rousseau F. Overview of the effectiveness of triple combination therapy in antiretroviral-naïve HIV-1 infected adults. AIDS 2001;15:1369-77
10. Vibhagool A, Cahn P, Schechter M, et al. Triple nucleoside treatment with abacavir plus the lamivudine/zidovudine combination tablet (COM) compared to indinavir/COM in antiretroviral therapy-naïve adults: results of a 48-week open-label, equivalence trial (CNA3014). Curr Med Res Opin 2004;20(7):1103-1114
11. Churchill D, Fisher M, Griffin A. Development of a patient completed questionnaire to measure adherence with HIV combination therapies. Fourth annual meeting of the British HIV Association, Oxford, UK, 27-29 March 1998
12. Montessori V, Heath B, Yip B, Hogg RS, O'Shaughnessy MV, Montaner JSG. Predictors of adherence to triple combination antiretroviral therapy. 7th Conference on retroviruses and opportunistic infections, San Francisco, CA, USA, 30 January-2 February 2000 [Abstract 72]
13. Arnsten J, Demas P, Farzadegan H, et al. Antiretroviral therapy adherence and viral suppression in HIV-infected drug users: comparison of self-report and electronic monitoring. Clin Infect Dis 2001;33:1417-23
14. Ostro D, Fox K, Kleeberger C, et al. Psychosocial correlates of incomplete adherence to HIV antiretroviral therapy (HAART): mental health matters. 8th Conference on retroviruses and opportunistic infections, Chicago, USA, 4-8 February 2001 [Abstract 484]
15. Gifford A, Bormann J, Shively M, Wright B, Richman D, Bozzette S. Predictors of self-reported adherence and plasma HIV concentrations in patients on multidrug antiretroviral regimens. J Acquir Immune Defic Syndr 2000;23:386-95
16. DeMasi RA, Graham NM, Tolson JM, et al. Correlation between self-reported adherence to highly active antiretroviral therapy (HAART) and virologic outcome. Adv Therapy 2001;18:163-73